

SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	on Public Policy			
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: ANGELA BROOKS	3		PHONE NUME 314-488-8 (
BUSINESS/ORGANIZATIO FOUR RIVERS HEA			DIRECTOI SERVICES	R OF PHARMACY
ADDRESS: 706 LARIAT LANE				
CITY: ROLLA			STATE: MO	ZIP: 65401
EMAIL: abrooks@fourrive	rs.org	ATTENDANCE: In-Person	SUBMIT D 5/2/202	DATE: 2 4 11:37 AM
THE INFORMAT	TION ON THIS FORM	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



WITNESS APPEARANCE FORM

BILL NUMBER: SB 751				DATE: 5/2/2024	
COMMITTEE: Special Committee	e on Public Policy				
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES	3
		WITNESS NAME			
INDIVIDUAL:					
WITNESS NAME: ARNIE C. "HONES	ST-ABE" DIENOFF-STAT	TE PUBLIC ADVOCAT	PHONE NUME	BER:	
BUSINESS/ORGANIZATIO	ON NAME:		TITLE:		
ADDRESS:			<u> </u>		
CITY:			STATE:	ZIP:	
EMAIL: arniedienoff@yah	oo.com	ATTENDANCE: Written	SUBMIT I 5/2/202	DATE: 24 11:59 PM	
THE INFORMA	TION ON THIS FOR	MIS DUBLIC DECOR	D LINDED CHY	DTED 610 PSMo	

I am in Support of this Bill. This Bill will bring needed Medications to Patients that make a huge difference in the daily lives of several Missourians. This Bill will also help keep open Rural Hospitals across our State. Pharmaceutical Companies have an obligation to keep Patients who are in need of the reduction in cost and access to the Medical Supplies.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	on Public Policy			
TESTIFYING:	✓ IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	DBBYIST:			
WITNESS NAME: CHASE CAMPBEL	L		PHONE NUME 573-864-0 9	
REPRESENTING: COX HEALTH			TITLE:	
ADDRESS: 124 E HIGH ST				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65101
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	OATE: 4 12:00 AM
THE INFORMAT	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy		·	
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: CRAIG THOMPSO	N		PHONE NUME 660-890-7	
BUSINESS/ORGANIZATION GOLDEN VALLEY	ON NAME: MEMORIAL HOSPITAL		TITLE: CEO	
ADDRESS: 1600 N. SECOND ST.				
CITY: CLINTON			STATE: MO	ZIP: 64735
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	OATE: 4 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751			DATE: 5/2/2024
COMMITTEE: Special Committee on Public Policy		•	
TESTIFYING: ✓ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
	WITNESS NAME		
REGISTERED LOBBYIST:			
WITNESS NAME: GERARD J. GRIMALDI		PHONE NUMB 816-404-3	
REPRESENTING: UNIVERSITY HEALTH/TRUMAN MEDICA	AL CENTER	TITLE:	
ADDRESS: 2301 HOLMES			
CITY: KANSAS CITY		STATE: MO	ZIP: 64145
EMAIL:	ATTENDANCE:	SUBMIT D 5/2/202	ATE: 4 12:00 AM
THE INFORMATION ON THIS FOR	RM IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.



BILL NUMBER: SB 751				DAT 5/2	E: /2024
COMMITTEE: Special Committee	e on Public Policy			•	
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFOR	RMATIO	NAL PURPOSES
		WITNESS NAME			
INDIVIDUAL:					
WITNESS NAME: JODIE GREGG			PHONE NU	JMBER:	
BUSINESS/ORGANIZATION	ON NAME:		TITLE:		
ADDRESS:			·		
CITY:			STATE:		ZIP:
EMAIL:		ATTENDANCE:		IT DATE: 2024 12:	:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CH	IAPTE	R 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy		•	
TESTIFYING:	✓ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	OBBYIST:			
WITNESS NAME: JORGEN SCHLEM	EIER		PHONE NUMB 573-634-48	
REPRESENTING: MO PHARMACY A	SSOC.		TITLE:	
ADDRESS: 213 E. CAPITOL A	VE.			
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65101
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	OATE: 14 12:00 AM
THE INFORMAT	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	on Public Policy		·	
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	BBYIST:			
WITNESS NAME: JUSTIN ALFERMAN	l		PHONE NUMB 636-667-1 0	
REPRESENTING: SSM HEALTH			TITLE:	
ADDRESS: 25 WOODFOX LANE	Ē			
CITY: HERMANN			STATE: MO	ZIP: 65041
EMAIL: justinalf@gmail.com	n	ATTENDANCE: In-Person	SUBMIT D 5/2/202	OATE: 4 9:57 AM
THE INFORMAT	ION ON THIS FORM	I IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	on Public Policy			
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO	FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: KAREN WHITE			PHONE NUME 573-663-2 3	
BUSINESS/ORGANIZATION BIG SPRINGS MEDICARE		O HIGHLANDS HEALTH	TITLE: CEO	
ADDRESS: PO BOX 157				
CITY: ELLINGTON			STATE: MO	ZIP: 63638
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	DATE: 24 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D LINDER CHA	PTER 610 RSMo



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	OBBYIST:			
WITNESS NAME: KATHI HARNESS			PHONE NUME 573-353-4	
REPRESENTING: HARNESS AND AS	SSOCIATES- ST. LUKE	's HEALTH SYSTEM	TITLE:	
ADDRESS: PO BOX 751				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65102
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	DATE: 14 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751			DATE: 5/2/2024
COMMITTEE: Special Committee on Public Policy			
TESTIFYING : ✓ IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
	WITNESS NAME		
BUSINESS/ORGANIZATION:			
WITNESS NAME: KATIE REICHARD EIKEN		PHONE NUME	BER:
BUSINESS/ORGANIZATION NAME: MO PRIMARY CARE ASSOCIATION		DIR. OF G AFFAIRS	OVERNMENT
ADDRESS:			
CITY: JEFFERSON CITY		STATE: MO	ZIP: 65109
EMAIL: kreichard@mo-pca.org	ATTENDANCE: In-Person	SUBMIT 0 5/2/202	DATE: 24 10:50 AM

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

MPCA and our 27 FQHC members with over 200 locations across the state ask for the support of this committee for SB 751.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy		,	
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: MARIAH HOLLABA	AUGH		PHONE NUME 573-893-3	
BUSINESS/ORGANIZATION CITIZENS MEMOR			TITLE:	
ADDRESS: 4712 COUNTRY CLUB DR				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65109
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	DATE: 4 12:00 AM
THE INFORMA	TION ON THIS FORM	I IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	on Public Policy		·	
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	BBYIST:			
WITNESS NAME: MEAGAN HOWERT	ON		PHONE NUMB 573-418-76	
REPRESENTING: MOSAIC LIFE CARI	E AND BJC HEALTH (CARE	TITLE:	
ADDRESS:				
CITY:			STATE: MO	ZIP:
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	ATE: 4 12:00 AM
THE INFORMAT	ION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy		•	
TESTIFYING:	✓ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	OBBYIST:			
WITNESS NAME: OLIVIA WILSON			PHONE NUMB	ER:
REPRESENTING: UNIVERSITY OF M	IISSOURI HEALTH CAF	RE	TITLE:	
ADDRESS: 217 E. CAPITOL				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65101
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	ATE: 4 12:00 AM
THE INFORMAT	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	OBBYIST:			
WITNESS NAME: ROB MONSEES			PHONE NUME 573-999-9	
REPRESENTING: MISSOURI HOSPIT	TAL ASSOCIATION		TITLE:	
ADDRESS: PO BOX 60				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65102
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	DATE: 24 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: SCOTT CROUCH			PHONE NUME 417-399-3	
BUSINESS/ORGANIZATIO OZARKS COMMUN	ON NAME: NITY HEALTH CENTER	2	TITLE: CEO	
ADDRESS: 18614 JACKSON S	ST.			
CITY: HERMITAGE			STATE: MO	ZIP: 65613
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	DATE: 14 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
INDIVIDUAL:				
WITNESS NAME: SHARON FENNEY	VALD		PHONE NUME	BER:
BUSINESS/ORGANIZATIO	ON NAME:		TITLE:	
ADDRESS:				
CITY:			STATE:	ZIP:
EMAIL: sharon.fennewald	@swissmeats.com	ATTENDANCE: Written	SUBMIT 0 5/1/202	PATE: 24 12:26 PM
THE INFORMATION ON THIS FORM IS PURI IC RECORD LINDER CHAPTER 610, RSMo				

I wanted to submit my support of the senate bill sponsored by Sen. Ben Brown to BAN ranked-choice voting in Missouri.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy		·	
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORG	ANIZATION:			
WITNESS NAME: TODD AHRENS			PHONE NUME	BER:
BUSINESS/ORGANIZATION HANNIBAL REGIO			TITLE: CEO	
ADDRESS: 6000 HOSPITAL D	R.			
CITY: HANNIBAL			STATE: MO	ZIP: 63401
EMAIL:		ATTENDANCE:	SUBMIT D 5/2/202	OATE: 4 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



WITNESS APPEARANCE FORM

BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	☑ IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFORM	ATIONAL PURPOSES
		WITNESS NAME		
INDIVIDUAL:				
WITNESS NAME: TONIANN RICHAR	RD		PHONE NUMI	BER:
BUSINESS/ORGANIZATIO	ON NAME:		TITLE:	
ADDRESS:				
CITY:			STATE:	ZIP:
EMAIL: toniann@hccnetw	ork.org	ATTENDANCE: Written	SUBMIT 5/2/202	DATE: 24 11:19 AM

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

As the CEO of an FQHC in West Central Missouri it is important to ensure our patients have access to their medications. FQHCs have a solid history of being fiscally and ethically responsible with the distribution and reconciliation of these programs and losing access to the 340B program would be detrimental to our public health care delivery system. In our organization, HCC Network, revenues from the 340B program support our enabling services such as transportation, housing and food insecurities.



WITNESS APPEARANCE FORM

BILL NUMBER: SB 751				DATE: 5/2/2024		
COMMITTEE: Special Committee	COMMITTEE: Special Committee on Public Policy					
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO	☐FOR INFO	RMATIONAL PURP	OSES	
		WITNESS NAME				
REGISTERED LO	BBYIST:					
WITNESS NAME: WILLIAM DANE			PHONE N 405-41 2			
REPRESENTING: HEALTHCARE DISTRIBUTION ALLIANCE SENIOR DIRECTOR, STATE GOVERNMENT AFFAIRS				ΓΕ		
ADDRESS: 10200 CREEK MEADOW DRIVE						
CITY: OKLAHOMA CITY			STATE: OK	ZIP: 73151		
EMAIL: wdane@hda.org		ATTENDANCE: Written		MIT DATE: 2024 10:57 AM		

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

*CorrectedMay 2, 2024The Honorable Terry ThompsonChair, Missouri House Special Committee on Public PolicySubmitted as TestimonyChairman Thompson, Vice Chair Hudson and Honorable Members of the Special Committee on Public Policy: On behalf of the Healthcare Distribution Alliance (HDA), I thank you for your time and review of Senate Bill 751 as perfected and passed, and extend that same gratitude to Senator Brown and Representative Peters who have worked with a variety of stakeholders. including the Missouri Hospital Association, to bring this language before you today after much input and discussion. Quickly, HDA is the vital link between the nation's pharmaceutical manufacturers and more than 350,000 pharmacies and healthcare settings around the country. An estimated 95% of prescription drugs are handled by our members, who save our nation's Healthcare System billions of dollars each year through ever-expanding logistics and efficiencies. Unlike other supply chain members, distributors business does not involve manufacturing pharmaceutical drugs, to include marketing, prescribing, or dispensing medications. Importantly, our role is on the "product movement" side of the product and not the "pricing" side. For the committee's reference, these are the primary topics discussed with the sponsors and other stakeholders: Wholesale distributors work under contract with pharmaceutical manufacturers. For the distribution services they provide, wholesalers charge manufacturers a bona fide service fee, as stipulated by federal law, that is not passed along to the subsequent purchaser. These service fees typically underwrite the cost of warehousing, ordering, special product handling services and transporting products to the thousands of ship-to points each distributor serves every day... In their role as a wholesale distributor, HDA members do not manufacture, market, prescribe or dispense medicines, nor do they set the list price of prescription drugs, set third party payor reimbursement or coverage for prescription drugs, influence prescribing patterns, or determine patient-benefit designs. Similarly, wholesalers are not directly engaged in the 340B program beyond fulfilling orders. • Manufacturers participating in the 340B program determine the price for their 340B drug products and provide this price to their wholesaler. Wholesalers will then load this price into 340B accounts for covered entities to place orders. Wholesale distributors DO NOT play a role in setting 340B pricing, nor are they privy to it, until manufacturers provide the pricing to the wholesaler. • Covered Entities, or a covered entity's designated contract pharmacy, will place orders through a designated 340B account. The wholesaler will then fulfill these orders at the 340B price. • Since wholesalers work on a fee-for-service contract with the manufacturer, there is no incentive or disincentive based on the customer type (they receive distribution fees whether the sale is at the 340B price, WAC or some other price point). • Any stipulation regarding the delivery or distribution of a 340B product would be solely determined by the manufacturer, and these decisions would be dictated to the wholesaler. Including wholesale distributors within 340B legislation would

hold the wholesaler accountable for the actions determined by a manufacturer, actions the wholesaler does not have oversight or influence over. • Not that the points above aren't important, but it is most imperative to note that the inclusion of wholesalers in the language as originally drafted would conflict with wholesalers' obligations under federal Drug Enforcement Administration (DEA) regulations with respect to how they handle orders for controlled substances. Similarly, for three wholesalers, the language would also contradict their obligations under the national Injunctive Relief requirements. This would result in the wholesaler being placed in an untenable position of choosing "which law to break" rather than serving the supply chain. On behalf of the Healthcare Distribution Alliance and each of our member companies, we believe that the intent of Senate Bill No. 751 as drafted before you today is met and, again, appreciate the conversations leading up to this hearing that will undoubtedly avoid unnecessary or unintended consequences were we to be included. Please feel free to reach out to me at (405) 412-7412 or wdane@hda.org if you have any questions.Best,/Will Dane/William M. DaneSenior Director, State Government AffairsHealthcare Distribution Alliance



WITNESS APPEARANCE FORM

BILL NUMBER: SB 751					TE: 2/2024	
COMMITTEE: Special Committee on Public Policy						
TESTIFYING:	☑IN SUPPORT OF	☐ IN OPPOSITION TO	FOR	INFORMATIO	ONAL PURPOSES	
		WITNESS NAME				
REGISTERED LO	OBBYIST:					
WITNESS NAME: WILLIAM DANE				ONE NUMBER: 05-412-7412		
REPRESENTING: HEALTHCARE DISTRIBUTION ALLIANCE SENIOR DIRECTOR, STATE GOVERNMENT AFFAIRS						
ADDRESS: 10200 CREEK MEADOW DRIVE						
CITY: OKLAHOMA CITY			ST O	ATE: K	ZIP: 73151	
EMAIL: wdane@hda.org		ATTENDANCE: Written		SUBMIT DATE: 5/2/2024 1 (
g				0.1.1.01		

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

May 2, 2024The Honorable Terry ThompsonChair, Missouri Senate Special Committee on Public PolicyTestimony in Support of, and Providing Information on, Senate Bill 751Chairman Thompson, Vice Chair Hudson and Honorable Members of the Special Committee on Public Policy:On behalf of the Healthcare Distribution Alliance (HDA), I thank you for your time and review of Senate Bill 751 as perfected and passed, and extend that same gratitude to Senator Brown and Representative Peters who have worked with a variety of stakeholders, including the Missouri Hospital Association, to bring this language before you today after much input and discussion.Quickly, HDA is the vital link between the nation's pharmaceutical manufacturers and more than 350,000 pharmacies and healthcare settings around the country. An estimated 95% of prescription drugs are handled by our members, who save the our nation's Healthcare System billions of dollars each year through ever-expanding logistics and efficiencies. Unlike other supply chain members, distributors business does not involve manufacturing pharmaceutical drugs, to include marketing, prescribing, or dispensing medications. Importantly, our role is on the "product movement" side of the product and not the "pricing" side. For the committee's reference, these are the primary topics discussed with the sponsors and other stakeholders:•

Wholesale distributors work under contract with pharmaceutical manufacturers. For the distribution services they provide, wholesalers charge manufacturers a bona fide service fee, as stipulated by federal law, that is not passed along to the subsequent purchaser. These service fees typically underwrite the cost of warehousing, ordering, special product handling services and transporting products to the thousands of ship-to points each distributor serves every day.•

In their role as a wholesale distributor, HDA members do not manufacture, market, prescribe or dispense medicines, nor do they set the list price of prescription drugs, set third party payor reimbursement or coverage for prescription drugs, influence prescribing patterns, or determine patient-benefit designs. Similarly, wholesalers are not directly engaged in the 340B program beyond fulfilling orders. • Manufacturers participating in the 340B program determine the price for their 340B drug products and provide this price to their wholesaler. Wholesalers will then load this price into 340B accounts for covered entities to place orders. • Wholesale distributors DO NOT play a role in setting 340B pricing, nor are they privy to it, until manufacturers provide the pricing to the wholesaler. •

Covered Entities, or a covered entity's designated contract pharmacy, will place orders through a designated 340B account. The wholesaler will then fulfill these orders at the 340B price.

Since wholesalers work on a fee-for-service contract with the manufacturer, there is no incentive or disincentive based on the customer type (they receive distribution fees whether the sale is at the 340B price, WAC or some other price point). • Any stipulation regarding the delivery or distribution of a 340B product would be solely determined by the manufacturer, and these decisions

would be dictated to the wholesaler.• Including wholesale distributors within 340B legislation would hold the wholesaler accountable for the actions determined by a manufacturer, actions the wholesaler does not have oversight or influence over. • Not that the points above aren't important, but it is most imperative to note that the inclusion of wholesalers in the language as originally drafted would conflict with wholesalers' obligations under federal Drug Enforcement Administration (DEA) regulations with respect to how they handle orders for controlled substances. Similarly, for three wholesalers, the language would also contradict their obligations under the national Injunctive Relief requirements. This would result in the wholesaler being placed in an untenable position of choosing "which law to break" rather than serving the supply chain. On behalf of the Healthcare Distribution Alliance and each of our member companies, we believe that the intent of Senate Bill No. 751 as drafted before you today is met and, again, appreciate the conversations leading up to this hearing that will undoubtedly avoid unnecessary or unintended consequences were we to be included. Please feel free to reach out to me at (405) 412-7412 or wdane@hda.org if you have any questions.Best,/Will Dane/William M. DaneSenior Director, State Government AffairsHealthcare Distribution A



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	\square IN SUPPORT OF	✓ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	OBBYIST:			
WITNESS NAME: BRIAN BERNSKOI	ETTER		PHONE NUME 573-636-2	
REPRESENTING: PHRMA			TITLE:	
ADDRESS: 101 E. HIGH				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65101
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	DATE: 24 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610, RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee	e on Public Policy			
TESTIFYING:	☐IN SUPPORT OF	✓ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
REGISTERED LO	OBBYIST:			
WITNESS NAME: DRUE DUNCAN			PHONE NUME 573-823-8	
REPRESENTING: PFIZER			TITLE:	
ADDRESS: 8501 S. WARREN	SCHOOL RD			
CITY: COLUMBIA			STATE: MO	ZIP: 65203
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	DATE: 14 12:00 AM
THE INFORMA	TION ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



BILL NUMBER: SB 751				DATE: 5/2/2024
COMMITTEE: Special Committee of	on Public Policy			
TESTIFYING:	☐ IN SUPPORT OF	✓ IN OPPOSITION TO		ATIONAL PURPOSES
		WITNESS NAME		
BUSINESS/ORGA	NIZATION:			
WITNESS NAME: KELLY GILLESPIE			PHONE NUME 690-9267	BER:
BUSINESS/ORGANIZATION N MISSOURI BIOTECH		ΓΙΟΝ	TITLE: EXEC DIR	ECTOR
ADDRESS: PO BOX 148				
CITY: JEFFERSON CITY			STATE: MO	ZIP: 65102
EMAIL:		ATTENDANCE:	SUBMIT 0 5/2/202	DATE: 4 12:00 AM
THE INFORMATION	ON ON THIS FOR	M IS PUBLIC RECOR	D UNDER CHA	PTER 610. RSMo.



WITNESS APPEARANCE FORM

BILL NUMBER: SB 751			ATE: 6 /2/2024		
COMMITTEE: Special Committee on Public Policy		·			
TESTIFYING : □IN SUPPORT OF	✓ IN OPPOSITION TO	☐FOR INFORMATIONAL PURPOSES			
WITNESS NAME					
BUSINESS/ORGANIZATION:					
WITNESS NAME: LILLY MELANDER			PHONE NUMBER: 202-993-0043		
BUSINESS/ORGANIZATION NAME: BIOTECHNOLOGY INNOVATION ORGANIZATION (BIO)		TITLE: DIRECTOR OF STATE GOVERNMENT AFFAIRS, BIO			
ADDRESS: 1201 NEW YORK NW SUITE 1300					
CITY: WASHINGTON		STATE: DC	ZIP: 20005		
EMAIL: Imelander@bio.org	ATTENDANCE: Written	SUBMIT DATE 5/1/2024 2			

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

BIO respectfully opposes SB 751, as it distorts the 340B program beyond the scope of federal statute and erroneously mischaracterizes manufacturers' responsibilities within the distribution process. SB 751 contains language that erroneously implies manufacturers can select which pharmacies can participate as a 340B contract pharmacy. Manufacturers are not involved with contracts between pharmacies and another provider, including a 340B covered entity. Furthermore, the 340B program's requirement is for manufacturers to provide discounted drugs to 340B covered entities, and they are not required to facilitate distribution to their contract pharmacies. Therefore, it is not appropriate for legislation to dictate whether a manufacturer must allow for distribution of drugs to any pharmacy regardless of participation in the 340B program. The legislation prohibits manufacturers from withholding 340B-discounted drug products from a pharmacy that has contracted with a 340B covered entity. The issue of contract pharmacy is currently being litigated in several federal courts, as there is no statutory requirement for manufacturers to extend 340B prices to contract pharmacies. Contract pharmacy was created through federal guidance. A sub-regulatory guidance that the Health Resources and Services Administration (HRSA) - the agency that issued it— itself has acknowledged is legally unenforceable. Contract pharmacies have contributed to exponential growth in the 340B program. In 2014, discounted purchases under the 340B Drug Discount Program totaled roughly \$9 billion. In 2021, the program reached approximately \$44 billion, equating to approximately 14% of gross US sales of brand-name drugs. According to an October 2020 study, the number of contract pharmacy arrangements in the program grew by 4,228% from 2,321 in 2010 to 101,469 in 2020, and as of July 2023 this number increased to 194,016. Additionally, the number of unique pharmacy locations has grown from approximately 1,300 in 2010 to roughly 33,000 in 2023. According to one analysis, "the average profit margin on 340B medicines commonly dispensed through contract pharmacies is an estimated 72% compared with just 22% for non-340B medicines dispensed through independent pharmacies." This explosive growth has occurred because it is extremely profitable for pharmacies to share in the 340B discount provided to covered entities. A contract pharmacy's average gross profit margin on a 340B medicine dispensed at a contract pharmacy is estimated at 72%, compared to just 22% when dispensed by an independent pharmacy. HB 1056 would further benefit contract pharmacies' profit margins rather than the vulnerable patients the 340B program seeks to protect and serve. We oppose legislation to address federal 340B issues, especially those that are not in the federal statute and are subject to pending litigation. Please do not hesitate to contact us for any further information.



WITNESS APPEARANCE FORM

BILL NUMBER: SB 751			DATE: 5/2/2024	
COMMITTEE: Special Committee on Public Policy				
TESTIFYING : □IN SUPPORT OF	☐ IN OPPOSITION TO	▼FOR INFORMATIONAL PURPOSES		
	WITNESS NAME			
INDIVIDUAL:				
WITNESS NAME: ROBERT POPOVIAN		PHONE NUM	BER:	
BUSINESS/ORGANIZATION NAME:		TITLE:		
ADDRESS:		·		
CITY:		STATE:	ZIP:	
EMAIL: rpopovian@gmail.com	ATTENDANCE: Written	SUBMIT 5/2/20	DATE: 24 1:00 AM	

THE INFORMATION ON THIS FORM IS PUBLIC RECORD UNDER CHAPTER 610, RSMo.

Dear Committee Chair and Members: Thank you for allowing me to provide you with the following written testimony concerning SB751. I am providing this testimony as a neutral observer. All of the data provided in this testimony is available online through a tool developed by the Pioneer Institute utilizing data from the Health Resources and Services Administration (HRSA) and Rand Corporation. The website for the tool is https://pioneerinstitute.org/340babuse/. The information I am providing summarizes the findings regarding the 340B program in Missouri.Key Points. Missouri's low-income taxpayers are required to utilize for-profit 340B contract pharmacies in Hawaii, amongst many other 44% of 340B contract pharmacies for the top five Missouri hospitals with the most states. contract pharmacies are based outside the state. According to a study published in the Journal of American Medical Association, almost 90% of contract pharmacies operating in the U.S. are not mailorder pharmacies. PBM owned pharmacy has the most number of contracts benefiting from federal program intended to support needy Missouri taxpayers. Half of the contract pharmacies intended to serve poor patients in Missouri are located in affluent neighborhoods. Top 5 Hospitals in **MissouriHospital** # of 340B Contract Pharmacies # of 340B Contract Pharmacies outside the State LinesSSM ST MARY'S HEALTH CENTER 125 (39%)SSM 317 **DEPAUL HEALTH CENTER SSM HEALTH SAINT** 262 98 (37%) **LOUIS UNIV HOSP 222** 119 (54%)SSM ST. JOSEPH HEALTH CENTER 202

79 (39%) **HEARTLAND REGIONAL MED CENTER136**

(57%)44% of 340B contract pharmacies for the top Missouri hospitals with the most contract pharmacies are based outside the state. Some of the pharmacies are in Hawaii.Percentage of Contract Pharmacies in High-Income Districts = 51%Percentage of Contract Pharmacies in Low-Income Districts = 49%1. Why so many contract pharmacies?2. Why are there so many contract pharmacies outside Missouri as far as Hawaii when most contract pharmacies are not mail order?3. Why are so many of the contract pharmacies in affluent neighborhoods?4. Why is the number one contract pharmacy in the state a PBM owned pharmacy and not a community pharmacy serving the patients in the community?5. Isn't it reasonable for biopharmaceutical companies to ask a contract pharmacy to provide evidence that the medicine they dispensed that the pharmacy acquired through the 340B discount program was dispensed to an actual 340B patient?340B is a great program that ought to be preserved. Unfortunately, for-profit contract pharmacies have taken hold of this worthwhile federal program for the sole intent of profiteering. The 340B program requires more transparency, not less. In fact, through transparency, pharmacies, and institutions that do right by patients will be rewarded. The passage of legislation denying the need for transparency and provision of data by contract pharmacies to ensure that the right patients benefit from this program is a step in the wrong direction.

77